ISSN: 2379-1764
Osamu Ishibashi
Laboratory of Biological Macromolecules, Graduate School of Life and Environmental Sciences,
Osaka Prefecture University
Japan
Dr. Osamu Ishibashi received his MSc from Tokyo Institute of Technology (Japan) in 1993. In the same year he joined a pharmaceutical company, Ciba-Geigy Japan (currently Novartis Pharma), and conducted basic research leading to the development of novel anti-osteoporosis drugs, including cathepsin K inhibitors. Based on the achievements in the company, he received his Ph.D from Nagaoka University of Technology (Japan) in 2000. He then accepted academic positions including a post-doctoral fellow in Max-Planck Institute of Biochemistry (Germany) and a senior scientist in Niigata University (Japan). In 2006, he joined Nippon Medical School as a senior assistant professor, and started new projects as to microRNA-mediated regulation of cell functions. In 2012, he accepted the current position (associate professor) in Osaka Prefecture University to develop original studies as to pathology-related genome-wide transcriptomics.
His research interest is in function of microRNAs in Placenta, pathology-related genome-wide transcriptomics, genetics, bone metabolism such as the estrogen-mediated and mechanical stress-mediated cellular responses of osteoblasts.